314 related articles for article (PubMed ID: 31612408)
21. Down-regulation of c-Fos/c-Jun AP-1 dimer activity by sumoylation.
Bossis G; Malnou CE; Farras R; Andermarcher E; Hipskind R; Rodriguez M; Schmidt D; Muller S; Jariel-Encontre I; Piechaczyk M
Mol Cell Biol; 2005 Aug; 25(16):6964-79. PubMed ID: 16055710
[TBL] [Abstract][Full Text] [Related]
22. Attenuated expression of the serum responsive T1 gene in ras transformed fibroblasts due to the inhibition of c-fos gene activity.
Kessler R; Zacharova-Albinger A; Laursen NB; Kalousek M; Klemenz R
Oncogene; 1999 Mar; 18(9):1733-44. PubMed ID: 10208434
[TBL] [Abstract][Full Text] [Related]
23. Hypertrophic agonists induce the binding of c-Fos to an AP-1 site in cardiac myocytes: implications for the expression of GLUT1.
Santalucía T; Christmann M; Yacoub MH; Brand NJ
Cardiovasc Res; 2003 Sep; 59(3):639-48. PubMed ID: 14499865
[TBL] [Abstract][Full Text] [Related]
24. FRA1 is essential for the maintenance of the oncogenic phenotype induced by
Barguilla I; Bach J; Peremartí J; Marcos R; Hernández A
Metallomics; 2020 Dec; 12(12):2161-2173. PubMed ID: 33313624
[TBL] [Abstract][Full Text] [Related]
25. Jun and Fos family protein expression in human breast cancer: correlation of protein expression and clinicopathological parameters.
Langer S; Singer CF; Hudelist G; Dampier B; Kaserer K; Vinatzer U; Pehamberger H; Zielinski C; Kubista E; Schreibner M
Eur J Gynaecol Oncol; 2006; 27(4):345-52. PubMed ID: 17009623
[TBL] [Abstract][Full Text] [Related]
26. Expression of Jun and Fos proteins in ovarian tumors of different malignant potential and in ovarian cancer cell lines.
Hein S; Mahner S; Kanowski C; Löning T; Jänicke F; Milde-Langosch K
Oncol Rep; 2009 Jul; 22(1):177-83. PubMed ID: 19513521
[TBL] [Abstract][Full Text] [Related]
27. [Transcription of c-fos gene and DNA binding activity of transcription factor AP-1 increase upon differentiation of mouse F9 teratocarcinoma cells].
Chuĭkin IA; Lianguzova MS; Pospelov VA
Tsitologiia; 2004; 46(12):1080-90. PubMed ID: 15747838
[TBL] [Abstract][Full Text] [Related]
28. Activation and inhibition of the AP-1 complex in human breast cancer cells.
Chen TK; Smith LM; Gebhardt DK; Birrer MJ; Brown PH
Mol Carcinog; 1996 Mar; 15(3):215-26. PubMed ID: 8597534
[TBL] [Abstract][Full Text] [Related]
29. Overexpression of JunB in undifferentiated malignant rat oral keratinocytes enhances the malignant phenotype in vitro without altering cellular differentiation.
Robinson CM; Prime SS; Huntley S; Stone AM; Davies M; Eveson JW; Paterson IC
Int J Cancer; 2001 Mar; 91(5):625-30. PubMed ID: 11267971
[TBL] [Abstract][Full Text] [Related]
30. ERK signaling pathway is involved in p15INK4b/p16INK4a expression and HepG2 growth inhibition triggered by TPA and Saikosaponin a.
Wen-Sheng W
Oncogene; 2003 Feb; 22(7):955-63. PubMed ID: 12592382
[TBL] [Abstract][Full Text] [Related]
31. Increasing the low lipid phosphate phosphatase 1 activity in breast cancer cells decreases transcription by AP-1 and expressions of matrix metalloproteinases and cyclin D1/D3.
Tang X; McMullen TPW; Brindley DN
Theranostics; 2019; 9(21):6129-6142. PubMed ID: 31534541
[TBL] [Abstract][Full Text] [Related]
32. Expression pattern of the AP-1 family in breast cancer: association of fosB expression with a well-differentiated, receptor-positive tumor phenotype.
Bamberger AM; Methner C; Lisboa BW; Städtler C; Schulte HM; Löning T; Milde-Langosch K
Int J Cancer; 1999 Oct; 84(5):533-8. PubMed ID: 10502734
[TBL] [Abstract][Full Text] [Related]
33. Stimulation of B-Raf increases c-Jun and c-Fos expression and upregulates AP-1-regulated gene transcription in insulinoma cells.
Langfermann DS; Rössler OG; Thiel G
Mol Cell Endocrinol; 2018 Sep; 472():126-139. PubMed ID: 29225069
[TBL] [Abstract][Full Text] [Related]
34. The role of the AP-1 transcription factors c-Fos, FosB, Fra-1 and Fra-2 in the invasion process of mammary carcinomas.
Milde-Langosch K; Röder H; Andritzky B; Aslan B; Hemminger G; Brinkmann A; Bamberger CM; Löning T; Bamberger AM
Breast Cancer Res Treat; 2004 Jul; 86(2):139-52. PubMed ID: 15319566
[TBL] [Abstract][Full Text] [Related]
35. Fra‑1 enhances the radioresistance of colon cancer cells to X‑ray or C‑ion radiation.
Endo S; Fujita M; Yamada S; Imadome K; Nakayama F; Isozaki T; Yasuda T; Imai T; Matsubara H
Oncol Rep; 2018 Mar; 39(3):1112-1118. PubMed ID: 29399696
[TBL] [Abstract][Full Text] [Related]
36. Naringenin targets ERK2 and suppresses UVB-induced photoaging.
Jung SK; Ha SJ; Jung CH; Kim YT; Lee HK; Kim MO; Lee MH; Mottamal M; Bode AM; Lee KW; Dong Z
J Cell Mol Med; 2016 May; 20(5):909-19. PubMed ID: 26861188
[TBL] [Abstract][Full Text] [Related]
37. c-Jun activation is required for 4-hydroxytamoxifen-induced cell death in breast cancer cells.
Madeo A; Vinciguerra M; Lappano R; Galgani M; Gasperi-Campani A; Maggiolini M; Musti AM
Oncogene; 2010 Feb; 29(7):978-91. PubMed ID: 19935718
[TBL] [Abstract][Full Text] [Related]
38. Developmental expression and activities of specific fos and jun proteins are functionally related to osteoblast maturation: role of Fra-2 and Jun D during differentiation.
McCabe LR; Banerjee C; Kundu R; Harrison RJ; Dobner PR; Stein JL; Lian JB; Stein GS
Endocrinology; 1996 Oct; 137(10):4398-408. PubMed ID: 8828501
[TBL] [Abstract][Full Text] [Related]
39. Expression of dominant negative Jun inhibits elevated AP-1 and NF-kappaB transactivation and suppresses anchorage independent growth of HPV immortalized human keratinocytes.
Li JJ; Rhim JS; Schlegel R; Vousden KH; Colburn NH
Oncogene; 1998 May; 16(21):2711-21. PubMed ID: 9652737
[TBL] [Abstract][Full Text] [Related]
40. Src induces urokinase receptor gene expression and invasion/intravasation via activator protein-1/p-c-Jun in colorectal cancer.
Leupold JH; Asangani I; Maurer GD; Lengyel E; Post S; Allgayer H
Mol Cancer Res; 2007 May; 5(5):485-96. PubMed ID: 17510314
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
